Lamifiban

Drugs

Volumn 57, Issue 2, 1999, Pages 215-221

  Dooley, Mukta ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; PLASMA PROTEIN;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG PROTEIN BINDING; HEART INFARCTION; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOGENESIS; UNSTABLE ANGINA PECTORIS;

ACETATES; ANIMALS; BLEEDING TIME; CLINICAL TRIALS; HUMANS; PLATELET AGGREGATION INHIBITORS; TYROSINE;

ANGINA; THROMBUS;

EID: 0033055111     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957020-00009     Document Type: Article

References (14)

1. Ro 44-9883 (Lamifiban) Platelet aggregation inhibitor. Investigational Drug Brochure, F. Hoffman-La Roche, 1997
2. News from the XVIIIth congress of the European Society of Cardiology. Br J Cardiol 1996; 3 (5): 154-5
3. Dagenais P, Libersan D, Merhi Y, et al. GPIIb/IIIa receptor blockade at reperfusion by lamifiban reduces infarct size in the dog [abstract]. Can J Cardiol 1997 Sep; 13 Suppl. C: 94-5
4. Takiguchi Y, Asai F, Wada K, et al. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis. Thromb Haemosl 1995 Apr; 73 (4): 683-8
5. Théroux P, Kouz S, Roy L, et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian Lamifiban Study. Circulation 1996 Sep 01; 94: 899-905
6. PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial. J Am Coll Card. In press
7. Becker RC, Ali O, Harrington RA, et al. Platelet inhibition with the glycoprotein IIb/IIIa receptor antagonist lamifiban in high risk patient subsets: studies to determine the correlation between platelet-mediated prothrombotic activity and clinical risk [abstract]. Circulation 1997 Oct 21; 96 Suppl.: 748
8. Lehne G, Nordal K, Midtvedt K, et al. Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction. Thromb Haemost 1998; 79: 1119-25
9. PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin or both in unstable angina. Circulation 1998 Jun; 97: 2386-95
10. Steiner B, Hofer U, Wittke B, et al. Plasma concentration of lamifiban and glycoprotein IIb-IIIa receptor occupancy best predict clinical outcome in patients with unstable angina: results from PARAGON A [abstract]. Eur Heart J 1998 Aug; 19: 598
11. Lave T, Saner A, Coassolo P, et al. Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor. J Pharm Pharmacol 1996; 48: 573-7
12. Moliterno DJ, Harrington RA, Newby K, et al. Pronounced reduction in long-term ischemic events with platelet IIb/IIIa antagonism among diabetics with unstable angina: PARAGON 6-month results [abstract]. Circulation 1997 Oct 21; 96 Suppl.: 474
13. Topol EJ, Califf R, Van der Werf F. The PARAGON B trial: a randomized, double-blind, placebo-controlled study of lamifiban (Ro 44-9883) in patients with unstable angina/non-Q wave myocardial infarction. Hoffmann-La Roche, 1997
14. Adgey AAJ. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Am Heart J 1998 Apr; 135: S43-55